Cancer Research UK appoints two new Trustees

Cancer Research UK

Cancer Research UK today (31 March) announced the appointment of two new Trustees to its Council: Michael Pragnell and Professor Anton Berns.

Michael Pragnell is expected to succeed David Newbigging as Chairman of Cancer Research UK in November. He was the founder Chief Executive Officer of Syngenta AG, a world leading company in crop protection and plant bioscience, and was formerly CEO of AstraZeneca plc’s crop protection business.

Professor Anton Berns is the Director of Research at The Netherlands Cancer Institute and Professor of Experimental Genetics of Inherited Diseases at the University of Amsterdam.

David Newbigging, Chairman of Cancer Research UK, said:

“We’re delighted to welcome Michael Pragnell and Professor Berns to our Council. Michael joins our Council after an outstandingly successful career as Chief Executive of Syngenta, prior to which he was with AstraZeneca and before that Courtaulds. In addition, he has considerable international experience having worked in the US and Continental Europe as well as in the UK.

“Anton Berns is well known to us and has served as a non-Trustee member of our Council Research Strategy Committee which oversees the research strategy of the Charity. He has also served on a number of Committees associated with us and we are fortunate to have such an eminent internationally acclaimed scientist on our Council.

“It’s expected that Michael will succeed me as Chairman of Cancer Research UK when I retire at the end of October this year and I look forward to working with him over the next few months.”